Sandoz

14 PBAC submissions on file, active 2015–2025. 86% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Adalimumab
  Rheumatology · Recommended with restriction · 2024$246M
• Aflibercept
  Ophthalmology · Recommended · 2025other sponsor
• Denosumab
  Endocrinology · Recommended · 2025other sponsor
• Epoetin lambda
  Haematology · Recommended with restriction · 2017—
• Etanercept
  Rheumatology · Recommended with restriction · 2025other sponsor
• Fluticasone propionate with salmeterol xinafoate
  Respiratory · Not recommended · 2016other sponsor
• Gemcitabine
  Oncology · Recommended · 2025—
• Leuprorelin
  Endocrinology · Recommended · 2024other sponsor
• Natalizumab
  Neurology · Recommended · 2025—
• Oxycodone hydrochloride
  Pain · Not recommended · 2015—
• Pegfilgrastim
  Oncology · Recommended · 2020other sponsor
• Rituximab
  Haematology · Recommended · 2021other sponsor
• Tacrolimus
  Dermatology · Recommended with restriction · 2025other sponsor

Therapy area mix

Activity by year

2015 (1) · 2016 (2) · 2017 (1) · 2018 (2) · 2019 (2) · 2020 (1) · 2024 (2) · 2025 (3)

Rejection patterns

Across 2 Not recommended decisions on file.

• 1×inability to back titrate the dose with a similar device
• 1×different delivery device requiring additional patient training and potentially causing confusion and non-compliance
• 1×single high strength presentation limiting suitability for many patients
• 1×no clinical need identified
• 1×no pressing clinical need established for the strength